Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats moderate-to-severe plaque psoriasis. Sold as Taltz. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Ixekizumab (sold as Taltz), first approved Mar 22, 2016, with 6 new uses approved and 0 published complete response letters.
First approved: Mar 22, 2016
Applications: 1
New uses approved: 6
Complete response letters: 0
Medicare spending, 2025: $727M
First approved in the EU: Apr 25, 2016
First approved in Japan: Jul 4, 2016
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 3 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
TaltzDrugs with a new indication and a new dosage for the treatment of non-radiographic axial spondyloarthritis in patients who have not responded sufficiently… · Eli Lilly Japan K.K. · Sep 25, 2020
TaltzDrugs with a new additional indication and a new dosage for the treatment of ankylosing spondylitis in patients who have not responded sufficiently to… · Eli Lilly Japan K.K. · Nov 22, 2019
TaltzDrugs with a new dosage indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients… · Eli Lilly Japan K.K. · Aug 21, 2018
Taltz, new ingredientDrugs with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in… · Eli Lilly Japan K.K. · Jul 4, 2016 · Review report
Clinical Trials
21 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
